Bavencio plus Inlyta extends median PFS in advanced RCC patients

18 February 2019

The combination of Bavencio (avelumab) and Inlyta(axitinib) significantly extended median progression-free survival (PFS) by more than five months compared with Sutent (sunitinib) as a first-line treatment for patients with advanced renal cell carcinoma (RCC), irrespective of PD-L1 expression (HR: 0.69 [95% CI: 0.56–0.84]; Bavencio+Inlyta: 13.8 months [95% CI: 11.1-NE]; Sutent: 8.4 months [95% CI: 6.9-11.1]; p<0.001).

The results from an interim analysis of the pivotal JAVELIN Renal 101 trial are published online in the New England Journal of Medicine, said Germany’s Merck KGaA (MRK: DE) and its partner on the research, US pharma giant Pfizer (NYSE: PFE), over the weekend. Inlyta and Sutent are both Pfizer-developed drugs.

Further, the objective response rate (ORR) was doubled with Bavencio+Inlyta versus Sutent in this population (51.4% [95% CI: 46.6-56.1] versus 25.7% [95% CI: 21.7-30.0]). The study is continuing for the other primary endpoint of overall survival (OS).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK